Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
OptiNose Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
OPTN
Nasdaq
2834
https://www.optinose.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for OptiNose Inc
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
- Mar 15th, 2024 7:34 pm
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
- Mar 10th, 2024 12:30 pm
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 2:50 pm
OptiNose Full Year 2023 Earnings: EPS Beats Expectations
- Mar 8th, 2024 10:58 am
Q4 2023 OptiNose Inc Earnings Call
- Mar 8th, 2024 2:41 am
OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...
- Mar 7th, 2024 6:54 pm
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
- Mar 7th, 2024 1:15 pm
Optinose Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Recent Operational Highlights
- Mar 7th, 2024 12:00 pm
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
- Feb 29th, 2024 9:40 pm
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
- Feb 15th, 2024 8:49 am
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
- Jan 18th, 2024 5:00 pm
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
- Dec 6th, 2023 12:00 pm
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 22nd, 2023 2:00 pm
Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),
- Nov 17th, 2023 12:55 pm
OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript
- Nov 11th, 2023 4:37 pm
OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating Efficiency
- Nov 9th, 2023 1:05 pm
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
- Nov 9th, 2023 12:00 pm
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
- Oct 27th, 2023 12:00 pm
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?
- Oct 24th, 2023 4:00 pm
Investors in OptiNose (NASDAQ:OPTN) have unfortunately lost 87% over the last five years
- Oct 5th, 2023 2:54 pm
Scroll